Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome

ClinicalTrials.gov ID: NCT00434473

Public ClinicalTrials.gov record NCT00434473. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk Patients With Sickle Cell Disease and Vaso-occlusive Crisis)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The study will be conducted at 15-20 US centers in a randomized, placebo-controlled, double-blind fashion. Enrollees will be hospitalized sickle cell disease (SCD) patients at-risk for acute chest syndrome (ACS) based on the presence of vaso-occlusive crisis (VOC), fever (T ≥38.0°C) and serum sPLA2 concentration ≥50 ng/mL.

Study identification

NCT ID
NCT00434473
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Anthera Pharmaceuticals
Industry
Enrollment
30 participants

Conditions and interventions

Eligibility (public fields only)

Age range
5 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2006 (Type not available)
Primary completion
Aug 2009 (Actual)
Completion
Dec 2009 (Actual)
Last update posted
Mar 4, 2014

2006 – 2009

United States locations

U.S. sites
6
U.S. states
6
U.S. cities
6
Facility City State ZIP Site status
Howard University Hospital Washington D.C. District of Columbia 20060 —
Children's Healthcare of Atlanta Atlanta Georgia 30342 —
Children's Memorial Hospital Chicago Illinois 60614 —
SUNY Downstate Medical Center Brooklyn New York 11203 —
Duke University Comprehensive Sickle Cell Center Durham North Carolina 27713 —
Virginia Commonwealth University Richmond Virginia 23219 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00434473, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 4, 2014 · Synced Oct 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00434473 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →